ALEXANDER OBORO: Open Payments
NPI 1346807849 · MILL HALL, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$814 in 49 payments from 9 companies in 2025. Trend: 2023 $1,327 · 2024 $959 · 2025 $814
Food & beverage: $814
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $233 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $213 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| ABBVIE INC. | 4 | $60 |
| Janssen Pharmaceuticals, Inc | 2 | $51 |
| E.R. Squibb & Sons, L.L.C. | 3 | $49 |
| Alkermes, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
Products named: INGREZZA, CAPLYTA, Auvelity, VRAYLAR, INVEGA SUSTENNA, COBENFY, UZEDY, AUSTEDO XR.
Industry payments across PA — which companies pay providers there.
